An antimesothelin-monomethyl auristatin E conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2630-2640

  Scales, Suzie J ^a   Gupta, Nidhi ^a   Pacheco, Glenn ^a   Firestein, Ron ^a   French, Dorothy M ^a   Koeppen, Hartmut ^a   Rangell, Linda ^a   Barry Hamilton, Vivian ^a   Luis, Elizabeth ^a   Chuh, Josefa ^a   Zhang, Yin ^a   Ingle, Gladys S ^a   Fourie O'Donohue, Aimee ^a   Kozak, Katherine R ^a   Ross, Sarajane ^a   Dennis, Mark S ^a   Spencer, Susan D ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7D9 ANTIBODY; ALPHA MESOTHELIN MONOMETHYL AURISTATIN E CONJUGATE; ANTIBODY; ANTIBODY CONJUGATE; ANTIMESOTHELIN IMMUNOTOXIN; ANTINEOPLASTIC AGENT; CITRULLINE; IMMUNOTOXIN; MESOTHELIN; MONOMETHYL AURISTATIN F; PROTEINASE; UNCLASSIFIED DRUG; VALINE; VEDOTIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MESOTHELIOMA; MICROTUBULE; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG SCREENING; GENETIC TRANSFECTION; IMMUNOLOGY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RANDOMIZATION;

ANIMALS; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MESOTHELIOMA; MICE; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918771947     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0487-T     Document Type: Article

References (47)

1. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
2. Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270:21984-90.
3. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6.
4. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18:858-68.
5. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-speci fic chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014;2:112-20.
6. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003;52:338-41.
7. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patientswith mesothelin- expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
8. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, et al. Major cancer regressions in mesothelioma after treatment with an antimesothelin immunotoxin and immune suppression. Sci Transl Med 2013;5:208ra147.
9. Niederfellner G, Bauss F, Imhof-Jung S, Hesse F, Kronenberg S, Staak R, et al. RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014, (abstr 4510).
10. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20.
11. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16:6132-8.
12. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett 2007;255:232-40.
13. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69.
14. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
15. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
16. + breast cancer. Clin Breast Cancer 2011;11:275-82.
17. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine - a novel mesothelin-targeting antibodydrug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48.
18. Mita MM, Ricart AD, Mita AC, Patnaik A, Sarantopoulos J, Sankhala K, et al. A phase I study of a CanAg-targeted immunoconjugate, huC242- DM4, in patients with Can Ag-expressing solid tumors. J Clin Oncol 2007;25:18s, (suppl; abstr 3062).
19. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82.
20. Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 2008;7:2599-608.
21. Hongo JA, Tsai SP, Moffat B, Schroeder KA, Jung C, Chuntharapai A, et al. Characterization of novel neutralizing monoclonal antibodies specific to human neurturin. Hybridoma 2000;19:303-15.
22. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
23. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
24. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
25. Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, et al. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res 2011;17:965-75.
26. Wen X, Lai CK, Evangelista M, Hongo JA, de Sauvage FJ, Scales SJ. Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol 2010;30: 1910-22.
27. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007;67:4924-32.
28. Resources IoLA. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
29. Pinheiro J, Bates D, DebRoy S, Sarkar D. TheRCore team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 2009;3:1-96.
30. Drees M, Dengler WM, Hendriks HR, Kelland LR, Fiebig HH. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 1995;31A:356-61.
31. Kuesters S, Maurer M, Burger AM, Metz T, Fiebig HH. Correlation of ErbB2 gene status, mRNA and protein expression in a panel of >100 human tumor xenografts of different origin. Onkologie 2006; 29:249-56.
32. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv speci fi c for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669-74.
33. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
34. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
35. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005;11:5840-6.
36. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non- Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
37. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007; 13:1571-5.
38. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97.
39. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identi fication of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
40. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004;35:357-66.
41. Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, Pastan I. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing ahuman carcinomaxenograft expressing mesothelin. Int J Cancer 1999;80:559-63.
42. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-speci fic cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540-7.
43. Leipold D, Mallet WG. Case Study: An Antibody -Drug Conjugate Targeting MUC16 for Ovarian Cancer. Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. Springer New York, New York; 2013. p. 221-39.
44. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 2007;67: 9055-65.
45. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
46. Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res 2012;32:5151-8.
47. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Robinson Diamond J, et al. A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. J Clin Oncol 2014;32:5s, (suppl; abstr 529).